TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · major macro event coming up
RANI

Rani Therapeutics Holdings Inc

Healthcare · Biotechnology

0.7611$ +1.6% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Balance Sheet

Rani Therapeutics Holdings Inc (RANI) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 61 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet RANI
Line item Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
– – – 79 82 77 137 124 115 104 108 108 96 84 70 58 54 44 44 37 24 17 10 59 52 61
– – – 75 77 69 132 120 109 98 101 101 89 76 63 51 41 32 32 30 18 11 5.0 53 47 57
– – – 73 77 69 130 117 108 97 27 27 19 7.6 5.0 5.9 6.9 4.5 4.3 3.8 10 10 4.1 19 9.6 4.9
– – – 73 77 69 130 117 108 97 98 98 87 75 61 49 40 31 30 28 16 10 4.1 50 43 53
– – – 1.7 – – – – – – – – 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.4 0.6 0.0 – 2.0 2.1 2.2
– – – – – – – – – – – – 0.4 -0.2 -0.2 – – – – – – – – – – –
– – – – 4.5 4.4 4.6 4.6 4.9 5.4 5.7 6.0 6.0 7.1 – – – – – – – – – – – –
– – – 193 201 201 5.3 2.6 4.7 5.7 22 34 35 35 36 32 39 38 38 33 29 26 22 17 16 13
– – – 5.3 7.1 9.4 5.3 2.6 4.2 5.3 7.2 4.8 5.2 5.7 7.3 8.0 13 17 20 20 20 21 19 13 14 11
– – – 1.4 1.9 3.9 – – 0.7 0.7 1.0 1.0 0.9 0.9 2.0 5.6 9.8 14 16 16 16 16 15 1.6 1.5 1.3
– – – 0.5 0.9 1.7 1.3 1.1 1.3 1.4 1.8 1.5 1.5 1.0 1.4 0.6 0.8 0.5 1.6 1.4 1.5 1.8 2.5 0.3 0.9 1.0
– – – 2.4 1.9 – – – – – 14 29 29 29 28 24 21 17 14 9.6 5.9 2.2 – – – –
– – – -113 -118 -124 51 47 53 48 42 37 31 24 18 13 7.4 2.8 3.1 2.0 -3.1 -5.6 -7.9 33 28 39
– – – -114 -120 -125 -3.1 -8.3 -15 -22 -30 -39 -47 -57 -66 -73 -80 -87 -94 -103 -110 -117 -122 -133 -140 -147
19 19 19 19 19 19 19 19 21 24 24 25 25 25 26 26 26 26 29 33 33 37 37 147 180 187

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?